Immune Checkpoint Inhibitors

Name
Immune Checkpoint Inhibitors
Accession Number
DBCAT005176
Description

Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells.

Drugs
DrugDrug Description
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
CemiplimabA programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma.
SpartalizumabSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
CamrelizumabCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
SintilimabNot Annotated
TislelizumabTislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
ToripalimabToripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
DostarlimabAn anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.
RetifanlimabNot Annotated
AMP-224Not Annotated
MEDI0680Not Annotated
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
EnvafolimabNot Annotated
CosibelimabNot Annotated
AUNP-12Not Annotated
CA-170CA-170 is a selective, small molecule inhibitor of PD-L1.
anti-OX40 antibody BMS 986178A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.
TremelimumabTremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part...
Drugs & Drug Targets
DrugTargetType
IpilimumabCytotoxic T-lymphocyte protein 4target
NivolumabProgrammed cell death protein 1target
PembrolizumabProgrammed cell death protein 1target
CemiplimabProgrammed cell death protein 1target
SpartalizumabProgrammed cell death protein 1target
CamrelizumabProgrammed cell death protein 1target
SintilimabProgrammed cell death protein 1target
TislelizumabProgrammed cell death protein 1target
ToripalimabProgrammed cell death protein 1target
DostarlimabProgrammed cell death protein 1target
RetifanlimabProgrammed cell death protein 1target
AMP-224Programmed cell death protein 1target
MEDI0680Programmed cell death protein 1target
AtezolizumabProgrammed cell death 1 ligand 1target
AvelumabProgrammed cell death 1 ligand 1target
DurvalumabProgrammed cell death 1 ligand 1target
EnvafolimabProgrammed cell death 1 ligand 1target
CosibelimabProgrammed cell death 1 ligand 1target
AUNP-12Programmed cell death 1 ligand 1target
CA-170Programmed cell death 1 ligand 1target
anti-OX40 antibody BMS 986178Programmed cell death 1 ligand 1target
TremelimumabCytotoxic T-lymphocyte protein 4target